Tempus AI Secures Ambry Genetics in $600M Diagnostics Expansion Move
Tempus AI Completes $600 Million Acquisition of Ambry Genetics, Bolstering Precision Medicine Efforts In a landmark move for the precision medicine industry, Tempus AI (NASDAQ: TEM) has finalized its acquisition of Ambry Genetics, a leading genetic testing company renowned for its work in understanding the intricate relationships between genetics and disease. The transaction, valued at … Read more